Exelixis Patents

Patent portfolio assigned to Exelixis (verified via public assignee records). Public oncology company (cabozantinib/Cabometyx). 'Notable customers' are commercial/clinical partners (Ipsen ex-US/Japan rights, Takeda Japan rights, Genentech/Roche and BMS clinical collaborations, Aurigene discovery license). Direct competitors are other oncology/RCC drug makers (BMS, Pfizer). Exelixis Inc. is assignee on multiple cabozantinib patents (e.g. US10159666B2, US9815789B2). Pfizer competitor flag carried a non-matching review-site URL; relationship is general oncology competition.